Design of SPECT for BNCT to measure local boron dose with GAGG scintillator

Murata, Isao; Kusaka, Sachie; Minami, Kentaro; Saraue, Nobuhide; Tamaki, Shunsuke; Kato, Ikunoshin; Sato, F.

doi:10.1016/j.apradiso.2021.110056

Cited by 12 publications

(8 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BNCT-SPECT [ 20 , 21 , 22 ] and radioisotope imaging modalities such as 4- 10 B-Borono-2- 18 F-fluoro-L-phenylalanine ( 18 F-FBPA) [ 23 , 24 , 25 , 26 ] offer a promising means of determining individual tumor-to-blood ratios (TBRs) for BNCT by providing detailed information on the distribution of boron within a patient’s tumor tissue. It should be noted that this imaging-based approach provides an average TBR value across the entire gross tumor volume, which may be influenced by variables such as tumor cellularity.…”

Section: Discussionmentioning

confidence: 99%

PK Modeling of L-4-Boronophenylalanine and Development of Bayesian Predictive Platform for L-4-Boronophenylalanine PKs for Boron Neutron Capture Therapy

Kim,

Won,

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

L-4-[(10B)]Boronophenylalanine (BPA) is an amino acid analogue with a boron-10 moiety. It is most widely used as a boron carrier in boron neutron capture therapy. In this study, a Bayesian predictive platform of blood boron concentration based on a BPA pharmacokinetic (PK) model was developed. This platform is user-friendly and can predict the individual boron PK and optimal time window for boron neutron capture therapy in a simple way. The present study aimed to establish a PK model of L-4-boronophenylalanine and develop a Bayesian predictive platform for blood boron PKs for user-friendly estimation of boron concentration during neutron irradiation of neutron capture therapy. Whole blood boron concentrations from seven previous reports were graphically extracted and analyzed using the nonlinear mixed-effects modeling (NONMEM) approach. Model robustness was assessed using nonparametric bootstrap and visual predictive check approaches. The visual predictive check indicated that the final PK model is able to adequately predict observed concentrations. The Shiny package was used to input real-time blood boron concentration data, and during the following irradiation session blood boron was estimated with an acceptably short calculation time for the determination of irradiation time. Finally, a user-friendly Bayesian estimation platform for BPA PKs was developed to optimize individualized therapy for patients undergoing BNCT.

show abstract

Section: Discussionmentioning

confidence: 99%

PK Modeling of L-4-Boronophenylalanine and Development of Bayesian Predictive Platform for L-4-Boronophenylalanine PKs for Boron Neutron Capture Therapy

Kim,

Won,

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…A precise real-time measurement of the 10 B spatial distribution in healthy and pathological tissues are required to take full advantage of BNCT selectivity, as it would improve the effectiveness of the BNCT, and therapy personalization for each patient. Many feasibility analyzes of a single-photon emission computed tomography (SPECT) instrument for quantifying the boron dose have been carried out over the years [ 101 ]. Some of them would provide only dosimetric data, such as the absolute number of BNCT reactions that occur within the measured region [ 102 , 103 ].…”

Section: Boron Analysis and Boron Imaging In Bnctmentioning

confidence: 99%

Clinical Viability of Boron Neutron Capture Therapy for Personalized Radiation Treatment

Skwierawska

López-Valverde

Balcerzyk

et al. 2022

Cancers

View full text Add to dashboard Cite

Boron Neutron Capture Therapy (BNCT) is a promising binary disease-targeted therapy, as neutrons preferentially kill cells labeled with boron (10B), which makes it a precision medicine treatment modality that provides a therapeutic effect exclusively on patient-specific tumor spread. Contrary to what is usual in radiotherapy, BNCT proposes cell-tailored treatment planning rather than to the tumor mass. The success of BNCT depends mainly on the sufficient spatial biodistribution of 10B located around or within neoplastic cells to produce a high-dose gradient between the tumor and healthy tissue. However, it is not yet possible to precisely determine the concentration of 10B in a specific tissue in real-time using non-invasive methods. Critical issues remain to be resolved if BNCT is to become a valuable, minimally invasive, and efficient treatment. In addition, functional imaging technologies, such as PET, can be applied to determine biological information that can be used for the combined-modality radiotherapy protocol for each specific patient. Regardless, not only imaging methods but also proteomics and gene expression methods will facilitate BNCT becoming a modality of personalized medicine. This work provides an overview of the fundamental principles, recent advances, and future directions of BNCT as cell-targeted cancer therapy for personalized radiation treatment.

show abstract

“…This technique has the potential to be an effective cancer treatment solution, but it is not yet widely used due to several challenges, including the lack of a real-time dose monitoring method. Several groups are investigating the feasibility of using special SPECT systems to assess the dose delivered to the patient by detecting the prompt gamma rays at 478 keV emitted in 94% of boron-neutron capture reactions [3][4][5]. We focused on the development of a scintillator-based detector for this application, which is read out by silicon photomultipliers (SiPMs) and custom-designed Application Specific Integrated Circuits (ASICs).…”

Section: Introductionmentioning

confidence: 99%

Study of the thermal neutron activation of a gamma-ray detector for BNCT dose monitoring

Colombo,

Caracciolo,

Mazzucconi

et al. 2024

J. Inst.

View full text Add to dashboard Cite

We present a study on the neutron activation of a gamma-ray detector for a BNCT-SPECT dose imaging system. The detector is based on a LaBr3(Ce+Sr) scintillator crystal, coupled with a matrix of Silicon Photomultipliers (SiPMs), read by a dedicated electronics system. This detector has successfully demonstrated to be capable to identify the 10B compounds when irradiating borated vials with thermal neutrons. However, a background signal around 478 keV was detected, suggesting the activation of the detector itself. This study aims to determine the origin of this background signal by simulating the two main parts of the detector, which are the crystal and electronic boards, in order to assess their contribution to the background signal. The results of the FLUKA simulations show that the neutron capture reactions on both the crystal and electronic boards cause a relevant background nearby the BNCT signal, thereby limiting the detector's sensitivity. To address this issue, a customized cadmium shielding has been developed. This solution was tested at the TRIGA Mark II research nuclear reactor of Pavia University, where experimental measurements and corresponding FLUKA simulations proved its effectiveness.

show abstract

Design of SPECT for BNCT to measure local boron dose with GAGG scintillator

Cited by 12 publications

References 20 publications

PK Modeling of L-4-Boronophenylalanine and Development of Bayesian Predictive Platform for L-4-Boronophenylalanine PKs for Boron Neutron Capture Therapy

PK Modeling of L-4-Boronophenylalanine and Development of Bayesian Predictive Platform for L-4-Boronophenylalanine PKs for Boron Neutron Capture Therapy

Clinical Viability of Boron Neutron Capture Therapy for Personalized Radiation Treatment

Study of the thermal neutron activation of a gamma-ray detector for BNCT dose monitoring

Contact Info

Product

Resources

About